On September 14, SBP GROUP rose 3.43% at open, trading at HK$5.43 per share, with turnover of HK$1.5444 million.

On the news front, the company announced that its wholly-owned subsidiary has entered into a share purchase agreement to acquire 100% equity of Sino Harmony Ventures Limited for RMB 4.48 billion in cash from executive director and major shareholder Xie Chengrun. The transaction will indirectly increase the company's stake in CT Tianqing from 60% to 65%, with completion expected on September 16. Based on CT Tianqing's trailing twelve-month adjusted net profit attributable to equity holders, the acquisition implies a price-to-earnings ratio of approximately 19 times and is expected to boost the group's adjusted attributable net profit by approximately RMB 3.5 billion, representing a 7.4% accretion. The deal follows a series of positive developments, including an exclusive licensing agreement with Cipla for cancer drug TQB2102 covering seven emerging markets with milestone payments of up to $123 million, FDA clinical trial approval for GPC3-targeted ADC drug TQB6426, and a buy rating initiated by Guosheng Securities with a target price of HK$8.20.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)